Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.61 |
| ▸ | DRD2 | P14416 | 3/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1538256 | 0.87 | HTR6 (0.60) | HTR6DRD2HTR1AHTR2A | |
| SCHEMBL6205803 | 0.76 | HTR6 (0.62) | HTR6 | |
| SCHEMBL4675288 | 0.76 | HTR6 (1.00) | HTR6DRD2HTR1AHTR2A | |
| SCHEMBL4309774 | 0.74 | HTR6 (0.82) | HTR6DRD2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL4309912 | 0.73 | HTR6 (0.80) | HTR6DRD2HTR1AHTR2A | |
| SCHEMBL4318310 | 0.73 | HTR6 (0.72) | HTR6DRD2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL6518370 | 0.73 | HTR6 (0.80) | HTR6DRD2HTR1AHTR2A | |
| SCHEMBL5698341 | 0.73 | HTR6 (0.80) | HTR6DRD2HTR1AHTR2A | |
| SCHEMBL4310106 | 0.72 | HTR6 (0.91) | HTR6DRD2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL6522832 | 0.72 | HTR6 (0.71) | HTR6DRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176705-A1 | Compounds useful in the treatment of cns disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-08-11 | — | — | US | disclosed |
| EP-1335722-A2 | COMPOUNDS USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002041889-A2 | INDOLSULFONYL COMPOUNDS USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176705-A1 | Compounds useful in the treatment of cns disorders | SLC18A2, CNR2, TPH2 | HTR6 22/4885DRD2 98/4885HTR1A 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.